FAL Lawyers
Home Our People Legal Services Intellectual Property Industry Expertise News & Resources Contact Us
Back to Resources

Investor Twilight Briefing

Investor Twilight Briefing

You are invited to a briefing by

Imugene Executive Chairman Paul Hopper

Minomic CEO Dr Brad Walsh

Invion CEO Dr Greg Collier


Imugene Limited

-          Recent $3M capital raise to underpin clinical programs

-          Developing next generation immunotherapeutic HER-Vaxx -- could outperform blockbuster cancer drug Herceptin

-          Phase 1b/2 trial in gastric cancer expected H215

-          Targeting big pharma deal following Phase 2 data


Minomic Limited

-          Breakthrough novel prostate cancer diagnostic test MiCheck™

-          Near-term opportunity -- global market release expected 2016

-          All data shows MiCheck™ is almost twice as accurate as existing PSA technology

-          Cap raising up to $5M closing soon


Invion Limited

-          Developing two novel respiratory drugs, INV102 (nadolol) and INV104 (zafirlukast) to treat chronic airway diseases including asthma, COPD

-          Key Phase 2 data from INV102 (nadolol) trial expected within weeks - positioning company for partnership deal or trade sale

-          Recent $1M placement to US institutional investor supports next stage development

-          Third drug asset INV103 (ala-Cpn10) to treat autoimmune diseases -- Phase 2 data recently announced and partnering discussions underway


These company briefings will be followed by canapés and drinks

4:15pm for 4:30pm start
Wednesday 7 October 2015

The Auditorium
Level 12, 15 William St

RSVP by 4pm 5 October 2015 to Jason Watson
on  jw@fal-lawyers.com.au 


This event is proudly sponsored by FAL Lawyers